Genmab — August 2024

[gentogen]

Ibrutinib may also improve the health (or fitness) of T cells thus making epcoritamab safer and/or more effective

[E_L]

I like seeing these small new epco trials instigated by hospitals/ University centers/ MD's , they indicate interest from the field to work with epco

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[bibob]

God morgen.

[LP90]

Godmorgen

[E_L]

Aug. 6, 2024,
Ram Selvaraju, H.C. Wainwright, reiterated the Buy rating on Genmab. The price target remains the same with $50.00. "Despite BioNTech’s decision to step back from the co-development of acasunlimab, Selvaraju’s confidence in the drug remains unshaken, as he finds the clinical results presented at ASCO 2024 to be highly encouraging." https://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-genmab-strong-clinical-results-and-solid-financial-valuation-1033645523

[E_L]

TEPEZZA (teprotumumab-trbw) generated $479 million of sales in the second quarter. AMGEN REPORTS SECOND QUARTER 2024 https://investors.amgen.com/news-releases/news-release-details/amgen-reports-second-quarter-2024-financial-results

[E_L]

Regulatory review of the New Drug Application (NDA) for TEPEZZA in Japan and multiple additional geographies continues.
A Phase 3 study of TEPEZZA in Japan continues to enroll patients with chronic or low clinical activity score TED.
A Phase 3 study evaluating the subcutaneous route of administration of TEPEZZA is enrolling patients with TED.

[JKY_VH]

Tak E L

[E_L]

Today, Exelixis announced it will discontinue the development of XB002, the company’s tissue factor (TF)-targeting ADC, as part of its portfolio prioritization efforts. Based on available data, the compound is unlikely to improve upon tisotumab vedotin or other competitor TF-targeting ADCs currently in development. https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-second-quarter-2024-financial-results-and

[lahn1]

Tak for nyhederne EL

[E_L]

i am sure there will be some Novo watchers here that can look our for any mim8 news today?

[gentogen]

Following regulatory interactions, Novo Nordisk now expects to submit Mim8 for the first regulatory approval during the first half of 2025.

[Raun]

Burde Genmab aktien egentlig ikke have steget, ovenpå udmeldingen at Biontech trak sig fra Gen1046?.... Er klar over at det selvfølgelig giver usikkerhed, når en partner trækker sig for et stof .Men at Genmab ikke går ud og søger ny aftale, eller selv overvejer at trække stikket fortæller jo også en hel del. - Tværtimod vælger Genmab selv at stå for udgifterne på et dyrt fase 3 forsøg. Hvilket må tolkes til at Genmab tror selv meget på stoffet, - og så må det jo egentlig være en gave at stå med

[Raun]

et stort set 100% eget stof, så tæt på mål?

[Raun]

Der vil være noglee royalties til Biontech, hvis stoffet kom på markedet..... Men det kan da vel max være 10%

[Bulder]

The program will be subject to payment of certain milestones and a tiered single-digit royalty on net sales by Genmab to BioNTech.

[gentogen]

På sin vis enig. Genmab skulle jo alligevel have afholdt 50% af fase 3, så merudgiften er begrænset set i forhold til potentielle gevinst.

[gentogen]

Så der nået frem til fase 3 til halv pris. Det er da meget smart...